Data strategy in an HLS/biotech company
Last reviewed: 2026-06-29 — see the freshness policy.
Learning objectives
After this chapter you will be able to:
- Frame a data strategy for an HLS/biotech organization, not just a platform.
- Apply FAIR principles and choose a data-architecture style (lakehouse / mesh / fabric).
- Explain the SA's role in data strategy and the biotech-specific wrinkles.
Why strategy, not just a platform
In biotech and HLS, data is the asset — the output of expensive experiments, trials, and care — and increasingly the fuel for AI. Yet most organizations' data is trapped in silos: R&D instruments, the LIMS, the EHR, the CRO's systems, claims feeds. A data strategy is the plan that turns that scattered data into a reusable, governed, AI-ready asset aligned to business goals. It is a level above the lakehouse and OMOP chapters — those are how; strategy is what, why, and in what order.
flowchart LR
Vision["1. Vision & value<br/>(what business outcomes?)"] --> Gov
Gov["2. Governance<br/>(FAIR, quality, compliance)"] --> Arch
Arch["3. Architecture<br/>(lakehouse / mesh / fabric)"] --> People
People["4. People & operating model<br/>(CDO, product owners, stewards)"] --> Value
Value["5. Value delivery<br/>(data products, AI, RWE)"] --> Vision
A five-part framework
- Vision & value. Tie data work to outcomes — faster drug discovery, AI-ready R&D, RWE for regulators, commercial insight. Without a value thesis, "data strategy" becomes a platform shopping list. Leadership (often a Chief Data Officer) owns the vision.
- Governance. Quality, lineage, access, and compliance as platform primitives (governance & data contracts) — plus the FAIR principles below. In regulated work this includes GxP data integrity / ALCOA+.
- Architecture. Pick a style for the org's shape (next section), built on the lakehouse and standard models (OMOP).
- People & operating model. Roles (CDO, data product owners, stewards, platform team), funding, and how decisions get made — the part that actually determines success.
- Value delivery. Ship data products and AI/RWE use cases iteratively; measure adoption, not just pipelines built.
FAIR — the north star for HLS data
The dominant principle set in life-science data strategy is FAIR: data should be Findable, Accessible, Interoperable, and Reusable. FAIR is what makes data AI-ready — the 2025–26 industry consensus is that the barrier to AI in pharma isn't models, it's non-FAIR data. Practically: catalog and richly describe data (Findable), control but enable access (Accessible), use standard models and vocabularies — FHIR/OMOP/terminologies — (Interoperable), and license/document for reuse (Reusable).
Choosing a data-architecture style
| Style | Idea | Fits when |
|---|---|---|
| Lakehouse | One governed platform, medallion layers | Most orgs; the default substrate (lakehouse) |
| Data mesh | Domain teams own data products; central self-serve platform + federated governance — see Data mesh in HLS | Large orgs with strong domains (R&D, clinical, commercial) and platform maturity |
| Data fabric | Metadata/virtualization layer over many sources | Lots of legacy systems you can't consolidate yet |
| Data-as-a-product | Treat each dataset as a product with an owner, SLA, contract | A discipline you can adopt within any of the above |
These are not exclusive: a common HLS pattern is a lakehouse substrate + data-as-a-product discipline, evolving toward mesh as domains mature.
Biotech-specific wrinkles
- R&D vs commercial divide. R&D data (instruments, assays, multi-omics) and commercial/clinical data (claims, EHR, RWD) have different shapes, owners, and regulations — the strategy must bridge them, not pretend they're one.
- Instrument & lab data. High-volume, heterogeneous output from sequencers, imagers, and lab instruments (via the LIS/LIMS) — capture it FAIR at the source.
- GxP data integrity. R&D/manufacturing data supporting submissions must satisfy ALCOA+ and 21 CFR Part 11 — strategy and governance must encode it.
- RWD acquisition & partnerships. Much value comes from external data (claims, registries) linked via tokenization; sourcing, contracts, and clean-room collaboration are strategy decisions.
- Build vs buy. Specialist platforms (Benchling, Veeva, etc.) vs a general lakehouse — a recurring trade-off.
A maturity model
A useful ladder to place an org and set the next step:
- Ad hoc — data in silos, copied by hand, no catalog.
- Managed — central platform, basic governance and access control.
- FAIR — cataloged, standard-modeled, quality-monitored, reusable.
- AI-ready — governed, FAIR data feeding ML/RWE with lineage and reproducibility.
The SA's role
You are rarely the CDO, but you turn strategy into architecture: choosing the platform style, encoding FAIR and governance as IaC and data contracts, designing the OMOP/FHIR backbone, and sequencing delivery so the first data products ship before the grand platform is "done." Strategy that never reaches an architecture is a slide deck; your job is to land it.
Check yourself
- Why is "data strategy" more than choosing a lakehouse?
- What do the four FAIR letters stand for, and why is FAIR the prerequisite for AI in pharma?
- Name two biotech-specific factors a generic enterprise data strategy would miss.